| Page 1718 | Kisaco Research
 

Matthew Bogyo

Group Leader and Professor
Stanford University School of Medicine

Matthew Bogyo

Group Leader and Professor
Stanford University School of Medicine

Matthew Bogyo

Group Leader and Professor
Stanford University School of Medicine
 

Marcus Groettrup

Chair of Immunology
Konstanz University

Marcus Groettrup

Chair of Immunology
Konstanz University

Marcus Groettrup

Chair of Immunology
Konstanz University
 

Lawrence Dick

Principal
Seofon Consulting

Lawrence Dick

Principal
Seofon Consulting

Lawrence Dick

Principal
Seofon Consulting
 

Kandaswamy Vijayan

CEO
Plexium

Kandaswamy Vijayan

CEO
Plexium

Kandaswamy Vijayan

CEO
Plexium
 

John Price

Assistant Professor
Brigham Young University

John Price

Assistant Professor
Brigham Young University

John Price

Assistant Professor
Brigham Young University
 

John Houston

CEO
Arvinas

John Houston

CEO
Arvinas

John Houston

CEO
Arvinas
 

James Winkler

Head of Degrader Technologies
Frontier Medicines

James Winkler

Head of Degrader Technologies
Frontier Medicines

James Winkler

Head of Degrader Technologies
Frontier Medicines
 

Hyunsun Jo

CEO
Pin Therapeutics

Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio.

Hyunsun Jo

CEO
Pin Therapeutics

Hyunsun Jo

CEO
Pin Therapeutics

Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio. He obtained his BA and PhD in Molecular Biology (Metabolic Diseases) at Seoul National University and Postdoc (aging-related diseases) at the Gladstone Institute (UCSF).

 

Frank Mercurio

CSO
BioTheryX

Frank Mercurio has over 25 years of research experience studying the molecular mechanisms underlying cancer and inflammation. Frank was Senior Director of Discovery Biology at Celgene where he initiated and successfully managed numerous Target and Drug Discovery programs. Among his key discoveries, Frank’s team elucidated the mechanistic process regulating activation of the NF-kB signaling pathway, which plays a critical role in the onset and progression of many types of cancer and inflammation.

Frank Mercurio

CSO
BioTheryX

Frank Mercurio

CSO
BioTheryX

Frank Mercurio has over 25 years of research experience studying the molecular mechanisms underlying cancer and inflammation. Frank was Senior Director of Discovery Biology at Celgene where he initiated and successfully managed numerous Target and Drug Discovery programs. Among his key discoveries, Frank’s team elucidated the mechanistic process regulating activation of the NF-kB signaling pathway, which plays a critical role in the onset and progression of many types of cancer and inflammation. This program resulted in the identification of several novel therapeutic targets within the NF-kB pathway, creating several internal and partnered drug discovery programs. Frank also pioneered the development of an internal E3 Ubiquitin Ligase Program to identify small molecule modulators of protein degradation, an emerging area of drug development with enormous therapeutic potential. Another major focus of Frank's work was to develop technologies that enable the elucidation of drug mechanism of action. While at Celgene, he implemented these technologies to advance the understanding of Thalidomide and Lenalidomide mechanism of action. 

 

Fleur Ferguson

Assistant Professor
UCSD

Dr. Ferguson received her M.Sc in Chemistry from Imperial College London, and her Ph.D in Chemistry from the University of Cambridge. She performed her postdoctoral research in the laboratory of Professor Nathanael Gray at Harvard Medical School and Dana-Farber Cancer Institute. She is currently and Assistant Professor in the Department of Chemistry & Biochemistry and the Skaggs School of Pharmacy and Pharmaceutical Sciences at U.C. San Diego.

Fleur Ferguson

Assistant Professor
UCSD

Fleur Ferguson

Assistant Professor
UCSD

Dr. Ferguson received her M.Sc in Chemistry from Imperial College London, and her Ph.D in Chemistry from the University of Cambridge. She performed her postdoctoral research in the laboratory of Professor Nathanael Gray at Harvard Medical School and Dana-Farber Cancer Institute. She is currently and Assistant Professor in the Department of Chemistry & Biochemistry and the Skaggs School of Pharmacy and Pharmaceutical Sciences at U.C. San Diego.